ERBB2 and gastroesophageal junction adenocarcinoma: Another phase 2a study of DKN-01 in combination with tislelizumab, an anti-PD-1 antibody, plus CAPOX chemotherapy in Her2-negative advanced gastric or gastroesophageal junction adenocarcinomas (DisTinGuish) showed prolongation of PFS and OS with a favorable safety profile.